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ABSTRACT
The purpose of this study was to determine the efficacy of intracavitary cisplatin
against local regrowth and metastasis after resection of a murine mammary
carcinoma and the ability of a biologic response modifier (Virulizinw) to enhance
chemotherapy. C3H-HeJ mice were injected with Gollin-B tumor cells. Once growth
reached 8 mm, tumors underwent marginal resection and the mice were assigned
randomly to intraperitoneal (IP) cisplatin, Virulizin, a controlled release cisplatin-
impregnated sponge (OPLA–Pt), a combination of treatments or no treatment and
were evaluated for local regrowth, metastasis, and toxicity at 14 or 60 days after
surgery.
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A possible beneficial interaction was seen between OPLA–Pt and Virulizin at
14 days. All cisplatin groups had significant advantages over controls in all
variables measured with OPLA–Pt displaying significant advantages over IP
cisplatin in local recurrence rate, tumor score, survival time, and delay in regrowth
at 60 days. No toxicity related to either cisplatin or Virulizin was observed.
Key Words: Carcinoma; Virulizin; Cisplatin; Controlled release
INTRODUCTION
Randomized clinical trials have demonstrated that
breast-conserving surgery (BCT) plus radiation therapy
(RT) is an alternative to mastectomy for most women
with early stage breast cancer (clinical stage I and II), and
that survival and recurrence rates are comparable (1–4).
Furthermore, other randomized clinical trials have
clearly demonstrated that the use of RT following BCT
substantially reduced the risk of local recurrence (4,5).
Most of the local recurrences in the ispilateral breast,
either after mastectomy or BCT, seem to be related to the
presence of residual cancer or positive axillary lymph
nodes (6).
The rate of local relapse with BCT and RT is still
considerable, with values reported from 2 to 21% for five
years (1,4,5,7–12). Because local recurrence is a
distressing event that dramatically affects quality of
life, and is associated with an increased risk of distant
metastasis and death (13), improved local-regional
control is an important goal. There is a need to
investigate novel ways of preventing local recurrence,
especially for those patients for whom RT may not be
suitable or readily available.
We have evaluated an intracavitary chemotherapy
system comprising a biodegradable polymer containing
8% cisplatin by weight (open cell polylactic acid–
platinum, OPLA–Pt). The OPLA–Pt system has been
demonstrated in dogs to have lower systemic toxicity
than seen with an equivalent dose of intravenous
cisplatin, while simultaneously achieving a local,
intracavitary concentration (in the tumor bed) as much
as 50 times that achieved by the peak intravenous level
(14). This cisplatin delivery system was used in clinical
patients in the treatment of canine nasal tumors (as a
radiation sensitizer) (15) and soft tissue sarcomas (16). In
addition, it has been used in a preliminary study on the
efficacy of OPLA–Pt in a murine mammary carcinoma
model (17). A decrease in local recurrence rates was
observed when OPLA–Pt was placed in the wound
cavity following incomplete resection of mammary
tumor. Control mice that received no treatment following
incomplete resection had 100% local tumor regrowth. No
clinically significant renal, bone marrow, or neural
toxicity was noted. In addition, OPLA–Pt has also been
used as an adjuvant to RT in the treatment of canine nasal
tumors as low sustained doses of cisplatin were shown to
enhance the radiation-induced cell killing in several
tumor types (15,18,19).
Considering the numerous advantages of OPLA–Pt, it
is possible that this method of local drug delivery would be
effective in decreasing the local recurrence rate after BCT.
Rodent models continue to be important in defining both
the etiology of breast cancer and in generating new
prevention and treatment strategies against this prevalent
tumor type. Although cisplatin is not commonly used for
the treatment of breast cancer in women, it was chosen in
this study due to it’s presence within the polymer (OPLA–
Pt) system. In addition, the goal of this study was to
evaluate the principle of local (intracavitary) chemother-
apy on local tumor regrowth. Pilot work demonstrated
efficacy of the OPLA–Pt following intracavitary use
within this mouse tumor model (17). Furthermore, the
potential of immunotherapy, using a biological response
modifier, to enhance the efficacy of either OPLA–Pt or
cisplatin given intraperitoneally was examined. The
biological response modifier (Virulizinw, Imutec Pharma,
Scarborough, Ontario, Canada), is a bovine bile-derived
extract that appears to be capable of stimulating the
immune system to eliminate cancer cells. It is a potent
activator of macrophages, as measured by cytokine release
and tumoricidal activity against various cell lines in
culture. In addition, Virulizin demonstrated inhibition of
pancreatic tumor xenografts in mice and appeared to
augment gemcitabine chemotherapy (20). Moreover, it is
now approved for use in Mexico for the treatment of
pancreatic cancer. The product is also being evaluated in
human clinical trials in the United States and Canada (21).
Cisplatin with a Biological Response Modifier 481
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METHODS
Animals
Test animals included 180 C3H-HeJ virgin female
mice, 4–6 weeks old with a mean weight of 21 g. They
were housed in an AALAC-approved facility in cages of
five animals each and kept in a temperature-controlled
environment with 12 hr cycles of light and darkness.
They were fed with standard rodent chow and water ad
libitum. All the procedures were approved by the
Colorado State University Animal Care and Use
Committee.
Cell Line
The mice were inoculated with murine mammary
carcinoma (MTG-B) by subcutaneous injection into the
mammary fat pad of the left flank. The MTG-B cell line
is a murine mammary adenocarcinoma characterized by
being locally aggressive (volume doubling time less than
48 hr) and metastatic (22–25). This tumor cell line is
easily transplantable in non-immunocompromised mice,
such as the C3H-HeJ strain. Previous work demonstrated
a 100% rate of regrowth following intracapsular
(marginal) tumor removal (17). The MTG-B cell
suspension was derived from tumors excised from
passage mice. The tumors were digested using
collagenase, filtered, supported in tissue culture media,
and a viability stain (trypan blue) was used to determine
an approximate number of live cells. A saline cell
suspension was created to result in an inoculation of
1:0 £ 106 of MTG-B tumor cells per mouse in a volume
of 0.125 mL. An equal volume of a mouse sarcoma
derived basement membrane growth promoter (Matri-
gelw, Becton Dickinson Labware, Bedford, MA) was
mixed with the tumor cell suspension to ensure optimal
tumor growth (26). Previous work demonstrated
consistent growth with 5 £ 105 to 1 £ 106 tumor cells
injected in saline alone, however, the addition of the
Matrigel resulted in a narrower growth time frame
(unpublished data).
A flow cytometry evaluation was performed on
mammary mouse tumors after they were surgically
excised from control mice in order to evaluate the tumor
cell kinetic parameters. These parameters included the
DNA index, labeling index, the duration of the S phase,
and the potential doubling time. Bromodeoxyuridine was
injected intravenously 2–4 hr prior to excision of the
tumor. Single cell suspensions were obtained by mincing
the tumor samples and disaggregating the cells in
phosphate-buffered saline using a Stomacherw (VWR,
Denver, CO). The cells were then filtered, counted, fixed
in 50% ethanol/citric acid-buffered saline, and stained.
Flow cytometry was performed on an EPICS V
cytometer (Coulter, Hialeah, FL).
Once inoculated, the mice were examined daily, the
injection site palpated, and any growth measured. Three
standard measurements were taken using a Vernier
caliper. When the tumor growth reached 8 mm in any
direction, surgery was performed. Typically, this
occurred 5–7 days after inoculation. General anesthesia
was induced and maintained with isoflurane and oxygen.
Surgical sites were clipped and aseptically prepared. The
tumors were marginally excised (histologically incom-
plete). However, an attempt was made to remove all
grossly evident tumor. The tumors were palpably
circumscribed, and resection on the pseudocapsule was
generally straightforward. Previous work demonstrated a
100% rate of regrowth following similar surgical
removal. The skin was closed in all mice with 3–0
nylon in a continuous pattern.
At the time of the surgery the mice were
randomized into six different treatment groups of 30
animals each. Group 1 (cisplatin) received intraper-
itoneal (IP) cisplatin (Platinolw Bristol Myers-Squibb,
New Brunswick, NJ) at 5 mg/kg (17–19); group 2
(OPLA–Pt) was implanted with the OPLA–Pt at
5 mg/kg within the wound bed; group 3 (OPLA–
Pt/Virulizin) received OPLA–Pt once and Virulizin
injected IP at a dose of 0.5 mL, once at the time of
surgery and the second time 7 days, post-operatively;
group 4 (cisplatin/Virulizin) was injected with IP
cisplatin and IP Virulizin, given under the same dosing
regimen; group 5 (Virulizin) received Virulizin alone
(given under the same dosing regimen); and group 6
(control) received no treatment. The redosing schedule
was chosen to mimic the clinical situation of induction
chemotherapy without maintenance therapy, which is
commonly employed in the treatment of solid tumors.
The mice were evaluated daily and the regrowth was
measured and recorded. Since differences in treatment
effects might not be seen early in the trial, the mice were
randomized into two follow-up groups (short term—
14 days and long term—60 days) of 15 animals from each
group. Following sacrifice, a complete necropsy was
performed to evaluate histologically the presence of
metastasis and local tumor recurrence as well as any sign
of toxicity due to cisplatin, Virulizin, or OPLA–Pt. The
evidence of tumor (macroscopic and microscopic) in any
organ (liver, lung, spleen, heart, abdomen, surgical site,
kidney) was recorded and described for each mouse.
Morello et al.482
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Therapeutic Agents
Biodegradable Delivery System
The OPLA–Pt devices used in this study were
composed of homogeneous D,L-polylactic acid, within
which cisplatin is incorporated at a concentration of 2.0%
(w/w). The polymer/drug construct is a porous body
(apparent density , 0.0504–0.0552 g/cm3), with an
internal architecture of partially closed, randomly sized,
shaped, and positioned intercommunicating interstices.
All structural partitions are incomplete, providing (i)
unrestricted communication between all internal void
chambers and (ii) multiple avenues of communication
from any void within the device to any location on the
unit’s surface. The void partitions are fenestrated with
additional porosities that are 1–5mm in diameter. All
partition surfaces are rendered hydrophilic to encourage
free flow of blood and interstitial fluids throughout the
unit’s internal network of spaces. The OPLA–Pt devices
were sterilized by exposure to 2.5–3.0 Mrads of gamma
radiation. Post-radiation polymer profiles were deter-
mined by gel permeation chromatography, with Mw ¼
160; 480 and a polydispersity of 1.51 (average of two
determinations).
Biological Response Modifier
Virulizin was obtained from Imutec Pharma (now
Lorus Therapeutics). Virulizin is a bovine bile-derived
extract that appears to be capable of stimulating the
immune system to eliminate cancer cells. It is a potent
activator of macrophages, as measured by cytokine
release and tumoricidal activity against various cell lines
in culture. In addition, Virulizin demonstrated inhibition
of pancreatic tumor zenografts in mice and appeared to
augment gemcitabine chemotherapy (20) and is now
approved for use in Mexico for the treatment of
pancreatic cancer. The product is also being evaluated
in human clinical trials in the United States and Canada.
It has been evaluated in over 450 patients for treatment of
pancreatic cancer and Kaposi’s sarcoma, with a very low
toxicity profile (21).
Statistical Analyses
Separate analyses were performed for the short- and
long-term group. Tumor regrowth, metastasis, and
histological tumor score were observed. The scoring
system used to classify the tumor regrowth was based on
histological criteria. A score of 0 meant no recurrence of
tumors, a score of 1 was given to tumors that were
characterized by scattered, individual cancerous cells.
When a small mass (2 mm) of tumor cells was identified, a
score of 2 was given, and a score of 3 indicates a large mass
(3–5 mm) with necrosis. Survival time (time from the
surgery until the sacrifice) and delay time (days from
treatment until regrowth) were also statistically analyzed.
Significance of the effect of the treatment and
Virulizin on the Kaplan–Meier product limit estimates
of delay and survival time were assessed using the
Lifetest procedure in SAS. Strata were defined by the
treatment and Virulizin groups. Significance tests
included the log-rank, Wilcoxon, and likelihood ratio
tests. These three significance tests (the log-rank,
Wilcoxon, and likelihood ratio tests) are reported in
this study because they emphasize different parts of the
survival curve. The Wilcoxon test puts greater emphasis
on differences earlier in the event history. The log-rank
test puts greater emphasis on differences later in the
event history. The likelihood ration test has an even
stronger emphasis on the latter part of the event history.
The significance of the effects of the treatment (cisplatin
or OPLA–Pt) and Virulizin on the percentage of
occurrence of regrowth, metastasis, and histological
tumor score were assessed using logistic regression via
the CATMOD procedure in the SAS software package.
Toxicity and Pharmacokinetic Evaluation
Following the efficacy trial, two groups of 21 four to
six week old female C3H-HeJ mice each were
implanted with 1:0 £ 106 MTG-B mouse carcinoma
cells within the inguinal fat pad. Following the growth of
8 mm diameter (in any plane), 10 and 15 mg/kg of 2%
(w/w) cisplatin within an open cell polylactic acid
polymer (OPLAw, THM Biomedical, Duluth, MN) was
implanted within the wound bed of each group,
respectively, following marginal resection of the tumors.
Seven mice each were sacrificed at 7, 14 and 21 days, and
blood and serum were obtained for complete blood
count, serum urea nitrogen (SUN), and platinum
concentration by atomic absorption spectroscopy. A
full necropsy was performed and tissues submitted for
histological evaluation, following standard preparation
and staining with hematoxylin and eosin. All the tissues
were reviewed by a single pathologist (BEP).
RESULTS
Flow cytometry studies of the tumors showed that all
of the tumors studied were aneuploid, with a DNA index
Cisplatin with a Biological Response Modifier 483
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of 1.6–1.63. The labeling index varied from 0.15 to 0.27,
with a mean of 0.2. Duration of the S phase ranged from
7.4 to 12.3 hr, with a mean value of 9 hr. Finally, the
potential doubling time ranged from 1.8 to 2.7 days, with
a mean of 2.1 days.
Short-Term Treatment Groups
The results of the short-term group (14 days) are
summarized in Table 1. Four of the mice were not
included in the study due to injection of tumor into the
body wall. No death was associated with the surgical
procedure. Furthermore, no clinical or histological
toxicity to cisplatin or Virulizin was seen. Thirteen
animals (15%) were sacrificed before the predetermined
endpoint because of weight loss presumed to be due to
cancer cachexia. All mice from groups 2 and 3 had local
microscopic reactions to the OPLA–Pt implant. Six of
the 29 in these two groups (21%) also showed local
reactions (inflammation, swelling) that did not affect the
outcome of the treatment. The results observed in the
short-term group suggested possible interaction between
Virulizin and OPLA–Pt. In many instances, the
frequency of the events of interest (regrowth, metastasis,
etc.) was low. However, with such a short duration for
this arm of the study, differences between groups may
not have been fully expressed.
Local Recurrence
The application of significance tests among all groups
was not possible because all of group 5 displayed local
recurrence within 14 days. However, an empirical
observation suggested that the administration of
Virulizin had some positive effects on chemotherapy.
Most notable were the differences in percentage of
regrowth for group 3 vs. group 2. These results suggest a
possible beneficial interaction between OPLA–Pt and
Virulizin early in the course of the disease, where
immunotherapy was given on a weekly basis.
Overall, differences among treatments (cisplatin,
OPLA–Pt, and control) were significant ðp , 0:001Þ:
Groups 1 and 2 (cisplatin and OPLA–Pt groups) had a
significantly smaller number of cases of regrowth than
the control animals ðp , 0:001Þ; but were not different
from each other ðp ¼ 0:436Þ: The difference between the
OPLA–Pt groups containing Virulizin and those without
Virulizin approached significance ðp ¼ 0:170Þ; whereas,
significant differences between IP cisplatin, with and
without Virulizin, were not observed.
Metastasis
The overall rate of metastasis was 4.65%. Therefore,
the low expected frequencies invalidated tests of
significance. Numeric differences between all groups
were small, which suggested that they were likely due to
chance alone.
Tumor Score
For this histological variable, the application of the
significance tests was not possible because of zero
frequencies in some groups. However, the data suggests
that Virulizin administration may have interacted with
cisplatin. Of particular interest is the difference in tumor
scores for group 3 vs. group 2. These results suggested a
beneficial interaction between OPLA–Pt and Virulizin
early in the course of the disease, especially since the
duration of the study coincided with the length of
Virulizin treatment.
Overall, differences between the treatment groups
were significant ðp , 0:001Þ with the cisplatin and
OPLA–Pt groups having significantly smaller tumors
than control ðp , 0:001Þ; but were not significantly
different from each other ðp ¼ 0:316Þ: Differences
Table 1
Local Tumor Regrowth and Metastasis Rates for the Short-Term Treatment Groups
Treatment Groups
Group 1
Cisplatin
(IP), n = 14
Group 2
OPLA–Pt,
n = 14
Group 3
OPLA–Pt/Virulizin,
n = 15
Group 4
Cisplatin/Virulizin,
n = 15
Group 5
Virulizin,
n = 15
Group 6
Control,
n = 15
Local regrowth 8 10 3 7 15 13
Metastasis 0 1 1 0 2 1
Median survival time (days) 14 14 14 14 12 14
Median tumor score 1 1 0 1 3 3
Morello et al.484
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between groups with and without Virulizin were not
statistically significant ðp ¼ 0:379Þ:
Survival Time
Survival time is defined as the time from surgery until
the planned sacrifice date. Eighty-four percent of all
subjects survived for 14-days duration of the short-term
study. All subjects survived for at least 11 days. This
minimal variation in response meant that differences
between animals in each of the groups were minimal.
Therefore, comparisons between groups were not
informative.
Delay Times in Tumor Regrowth
Differences in regrowth times between treatment
groups were significant ðp , 0:001 for log-rank,
Wilcoxon, and likelihood ratio tests). The control
group had a tumor-regrowth delay time shorter than for
either the cisplatin or OPLA–Pt groups. More notably,
delay time was significantly longer for OPLA–Pt than
for cisplatin ðp , 0:001 for each of the log-rank,
Wilcoxon, and likelihood ratio tests). Differences
between the control group and the one given Virulizin
alone were likely due to chance alone ðp ¼ 0:375; 0.283,
0.409 for the log-rank, Wilcoxon, and Likelihood ration
tests, respectively).
Long-Term Treatment Groups
The same number of animals were used in the long-
term study as in the 14 day groups described above.
However, two mice were not included in the long-term
study due to injection of tumor cells into the body wall,
as determined by post-mortem examination. One death
was associated with hemorrhage after surgery. No
clinical or histological toxicity due to IP cisplatin
(0.5 mg/kg) or IP Virulizin was seen. Sixty-three mice
(72.4%) were sacrificed before the end of the study
because of probable cancer cachexia. Most of them
belonged to groups 5 and 6. All the mice from group 2
and 3 had histological local reactions to the OPLA–Pt
implant. Seven of the 30 mice (23%) in the OPLA–Pt
group also displayed evidence of local reactions
(infection, swelling). The data for the long-term group
are summarized in Table 2.
Local Recurrence
The interaction of Virulizin with chemotherapy was
not significant ðp ¼ 0:947Þ: However, note that the
Virulizin treatment was discontinued after the second
week of the study. It was not possible to obtain the p
values for significance of the differences between all the
three treatments (OPLA–Pt, cisplatin, and control)
because of the 100% regrowth rate for the control
animals. This meant there was no variation in response
for that category, making it impossible to compute
standard errors and p values. The difference in the rate of
recurrence between OPLA–Pt and the cisplatin treat-
ment groups was highly significant ðp , 0:001Þ; with
OPLA–Pt being more effective at preventing local
recurrence. The recurrence rate in OPLA–Pt treated
subjects was half that of the cisplatin-treated subjects.
Metastasis
The interaction of Virulizin with cisplatin (either
cisplatin or OPLA–Pt) was not significant ðp ¼ 0:195Þ:
Both the OPLA–Pt and cisplatin groups had significantly
lower metastasis rates than control ðp , 0:001Þ:
Although the rate of metastasis was lower in cisplatin
than in OPLA–Pt groups, this difference was not
significant ðp ¼ 0:404Þ:
Table 2
Local Tumor Regrowth and Metastasis Rates for the Long-Term Treatment Groups
Treatment Groups
Group 1
Cisplatin (IP),
n = 14
Group 2
OPLA–Pt,
n = 15
Group 3
OPLA–Pt/Virulizin,
n = 15
Group 4
Cisplatin/Virulizin,
n = 15
Group 5
Virulizin,
n = 13
Group 6
Control,
n = 15
Local regrowth 10 5 7 13 13 15
Metastasis 2 2 6 3 7 10
Median survival time (days) 41 60 43 37 18 16
Median tumor score 3 0 0 3 3 3
Cisplatin with a Biological Response Modifier 485
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Tumor Score
The interaction of Virulizin with either chemotherapy
was not significant ðp ¼ 0:998Þ: Two of the treatment
methods (OPLA–Pt and OPLA–Pt/Virulizin) markedly
reduced the median tumor score. In addition, animals in
the OPLA–Pt-treated group had significantly greater
frequencies of lower tumor scores than did those treated
with IP cisplatin ðp , 0:001Þ:
Survival Time
Differences between the treatment groups were
significant ðp , 0:001 for log-rank, Wilcoxon, and
likelihood ratio tests). The control group had shorter
survival times than either the cisplatin or OPLA–Pt
groups. More notably, survival times were significantly
longer for OPLA–Pt than for cisplatin groups ðp ¼
0:012; 0.042, and 0.020 for the log-rank, Wilcoxon, and
likelihood ratio tests, respectively). Differences in
survival time for groups containing Virulizin were not
significant ðp ¼ 0:285; 0.356, and 0.358 for the log-rank,
Wilcoxon, and likelihood ratio tests, respectively).
Figure 1 shows Kaplan–Meier survival curves of
survival time estimated by the treatment group. They
indicate that not only is there a clear advantage of
treatment over control groups, but that OPLA–Pt is
superior to IP cisplatin in extending survival time.
Delay Times in Tumor Regrowth
Differences between treatment groups were significant
ðp , 0:001 for log-rank, Wilcoxon, and likelihood ratio
tests). The control group had shorter delay than cisplatin
or OPLA–Pt groups. More notably, delay times were
significantly longer for OPLA–Pt than for cisplatin ðp ¼
0:014; 0.041, and 0.002 for the log-rank, Wilcoxon, and
likelihood ratio tests, respectively). Differences between
groups given Virulizin were not statistically significant
ðp ¼ 0:392; 0.542, 0.417 for log-rank, Wilcoxon, and
likelihood ratio tests, respectively). Figure 2 shows
Kaplan–Meier survival curves of tumor regrowth-delay
time estimated by the treatment group. Again, OPLA–Pt
exhibits a significantly greater delay than cisplatin, which
is better than the control group.
Toxicity and Pharmacokinetic Evaluation
Clinical toxicity from any of the therapies was not
observed, in either the short- or long-term groups, as
all the mice continued to eat, drink, and behave
normally. Following this initial trial, blood analysis (Pt
levels, complete blood count, and blood urea nitrogen)
was done in a separate group of mice implanted with
OPLA–Pt at 10 and 15 mg/kg. In these two groups,
neutropenia was seen, yet changes in kidney-associated
values were not observed. The platinum serum levels
were similar, independent of dose. Peak serum
platinum levels of 0.7 and 0.3mg/mL appeared at
day 7 and tapered to day 21; 0.3 and 0.1 for the 15
and 10 mg/kg groups, respectively. Kidney toxicity was
also histologically evaluated after the mice were
sacrificed and no evidence of damage was seen.
Figure 1. Kaplan–Meier survival function estimates for
survival time by treatment in the long-term (60 days) group.
Significantly prolonged survival was evident in mice treated
with OPLA–Pt within the resection wound (1) and mice treated
with intraperitoneal cisplatin (2) compared to mice not treated
(3) following marginal tumor removal.
Figure 2. Kaplan–Meier survival function estimates for
tumor growth delay time by treatment in the long-term
(60 days) group. Significantly delayed tumor regrowth was
evident in mice treated with OPLA–Pt within the resection
wound (1) compared to mice treated with intraperitoneal
cisplatin (2) or the mice not treated (3) following marginal
tumor removal.
Morello et al.486
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DISCUSSION
The aim of this study was to investigate alternative
methods of decreasing local recurrence and metastasis
rates following conservative breast cancer surgery in a
rodent model. Most recurrences in breast tissue after
conservative surgery and RT are at or near the site of the
primary tumor (23). Patients appear to have a better
prognosis when the incidence of local recurrence is less
after mastectomy (27). The reason may be due to the fact
that local relapse after BCT usually develops from
residual foci of primary disease rather than from
metastatic spread (27). An intracavitary delivery system
of chemotherapy placed directly in the wound bed could
be effective against microscopic tumor disease either
when used alone or in combination with immunotherapy
or even radiation.
The OPLA–Pt polymer system used in this study is
able to release high concentrations of the chemother-
apeutic agent (cisplatin) over time in the tumor excision
bed (14). Furthermore, there is systemic absorption of
cisplatin, so that the serum levels are high enough to be
effective against micrometastatic disease, at least in dogs
with osteosarcoma (28). In the murine mammary
carcinoma model used in this study, the tumors were
excised marginally so that microscopic tumor foci were
left in the wound bed to simulate a conservative surgical
procedure with residual disease. The high recurrence rate
seen in most of the mice after surgery demonstrates that
tumor excision was marginal. Moreover, this adenocar-
cinoma cell line has been shown to be locally aggressive
(18–20). Flow cytometry data indicate that it has a
potential doubling time of 2 days and displays a high-
labeling index. These results imply that the tumor was
obtained from the same clonogen and that there was a
consistent cell line implanted in each mouse.
The results of this study showed that the OPLA–Pt
intracavitary chemotherapy system has a positive effect
against local tumor recurrence, tumor metastasis, and
survival time. It is also successful in delaying the time of
tumor regrowth. Both cisplatin given IP and local
OPLA–Pt treatments result in significantly greater
efficacy over the control group in all variables measured.
In addition, OPLA–Pt had significant advantage over IP
cisplatin in recurrence rate, tumor score, survival time,
and tumor regrowth-delay.
Interestingly, the tumor recurrence rate in mice that
received OPLA–Pt was higher in the short-term group
than in the long-term group. This marked difference in
tumor recurrence rate (71 vs. 33%) and the median tumor
score (which was 1 in the short-term group vs. 0 in the
long-term group) could be due to a delay in the rate of
tumor death, with histological evidence of tumors being
observed at 14 days that would eventually succumb to
cisplatin. Conversely, since OPLA–Pt is left at the
surgical site, it may result in a delayed increase in the
local platinum concentration in the tumor bed, resulting
in more effective control of regrowth that manifests itself
over a longer time course (.14 days).
Overall, the results from the short-term group were
less informative than those from the long-term group. In
many instances, differences in events of interest (local
recurrence, metastasis, etc.) were small, and might not
have been fully expressed. However, the short-term
group was quite informative regarding the interaction of
Virulizin and cisplatin. While there was little evidence
that Virulizin given by itself was effective in this model,
there was a marked decrease in local recurrence in the
short-term group by administering Virulizin along with
OPLA–Pt (decrease from 71 to 20%; p ¼ 0:017Þ: This
effect was lost in the long-term group (Table 2). This
may be due to discontinuance of the Virulizin therapy
after the second week of the study. In a previous study
with pancreatic tumor zenografts, significant growth
inhibition was noted with Virulizin alone when given
daily for 14 days. Similarly, in that study, Virulizin
potentiated the chemotherapy agent gemcitabine (20).
These data indicate that immunotherapy with Virulizin
may be a useful adjuvant to intracavitary chemotherapy.
However, no such effect was observed with IP cisplatin
and Virulizin, suggesting that systemic administration of
cisplatin may interfere with the effects of Virulizin.
In both the short- and long-term groups, cisplatin was
effective at diminishing local regrowth and preventing
metastasis, with OPLA–Pt being superior to IP cisplatin.
Coupled with the lower incidence of adverse reactions
and toxicity, this work indicates that OPLA–Pt may be a
viable treatment option following tumor excision.
The choice of using cisplatin in this study was made
because of previous experience with OPLA – Pt
(14,16,17,28). It is recognized that this particular
chemotherapeutic agent is not the most effective
systemically administered drug against breast cancer.
In addition, the OPLA–Pt was not used at the maximum
tolerated dose based on the subsequent dose escalation
study. The results may have been different if higher
dosages of the OPLA–Pt had been used. However, the
goal of the study was to evaluate whether an intracavitary
or local approach to chemotherapy could be effective
against local tumor relapse in a breast tumor model. It
suggests that such a delivery system using different
chemotherapy agents, such as paclitaxel, may be even
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more effective against mammary tumors. Such studies
are currently under investigation.
In addition, the evaluation of intracavitary che-
motherapy in rodent models that more closely mimic
human breast carcinoma or large animal spontaneous
mammary tumor may be indicated. Dogs are
considered to be a valid tumor model system for a
comparison with humans (29). They develop tumors
twice as frequently as in women and some canine
malignancies (i.e., mammary tumors) have histopatho-
logical and biological behavior similar to human
tumors (30). Most canine tumors progress at a more
rapid rate than in people, making it easier to
accumulate experimental data in a relatively short
period. Moreover, one could determine whether
significant platinum levels could be reached in regional
lymph nodes after OPLA–Pt implantation, providing
the additional benefit of treating tumor cells that have
spread to regional lymph nodes. It has been observed
that local recurrence is seen in about 25% of patients if
there is involvement of axillary nodes; whereas if there
is not, local recurrence is seen in only about 5% of
patients (23).
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